Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D02ZPV
|
||||
| Former ID |
DNC006415
|
||||
| Drug Name |
UCB-101333-3
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [528765] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C17H26N4
|
||||
| Canonical SMILES |
CC1=C(N=C(N=C1NC2CC2)C3CC3)N4CCCCCC4
|
||||
| InChI |
1S/C17H26N4/c1-12-15(18-14-8-9-14)19-16(13-6-7-13)20-17(12)21-10-4-2-3-5-11-21/h13-14H,2-11H2,1H3,(H,18,19,20)
|
||||
| InChIKey |
XMDRTFUFPOAGDR-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | CAMP-specific 3',5'-cyclic phosphodiesterase 4B | Target Info | Inhibitor | [527990] | |
| CAMP-specific 3',5'-cyclic phosphodiesterase 4A | Target Info | Inhibitor | [527990] | ||
| Muscarinic acetylcholine receptor M3 | Target Info | Inhibitor | [528765] | ||
| Type IV phosphodiesterase | Target Info | Inhibitor | [527990] | ||
| KEGG Pathway | Purine metabolism | ||||
| cAMP signaling pathway | |||||
| Morphine addictionhsa00230:Purine metabolism | |||||
| Morphine addictionhsa04020:Calcium signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Cholinergic synapse | |||||
| Regulation of actin cytoskeleton | |||||
| Insulin secretion | |||||
| Salivary secretion | |||||
| Gastric acid secretion | |||||
| Pancreatic secretionhsa00230:Purine metabolism | |||||
| Morphine addiction | |||||
| NetPath Pathway | IL5 Signaling Pathway | ||||
| IL2 Signaling Pathway | |||||
| PathWhiz Pathway | Gastric Acid ProductionPW000052:Purine Metabolism | ||||
| WikiPathways | G Protein Signaling Pathways | ||||
| Myometrial Relaxation and Contraction Pathways | |||||
| Nuclear Receptors Meta-Pathway | |||||
| Opioid SignallingWP35:G Protein Signaling PathwaysWP58:Monoamine GPCRs | |||||
| Calcium Regulation in the Cardiac Cell | |||||
| Regulation of Actin Cytoskeleton | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Integration of energy metabolism | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| GPCRs, OtherWP35:G Protein Signaling Pathways | |||||
| TSH signaling pathway | |||||
| References | |||||
| Ref 527990 | Bioorg Med Chem Lett. 2006 Apr 1;16(7):1834-9. Epub 2006 Jan 24.First dual M3 antagonists-PDE4 inhibitors: synthesis and SAR of 4,6-diaminopyrimidine derivatives. | ||||
| Ref 528765 | Bioorg Med Chem Lett. 2007 Jun 1;17(11):3077-80. Epub 2007 Mar 19.Dual M3 antagonists-PDE4 inhibitors. Part 2: Synthesis and SAR of 3-substituted azetidinyl derivatives. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.